Duquesne Family Office’s Cidara Therapeutics CDTX Stock Holding History

Duquesne Family Office’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-49,495	Closed	-$10.9M	–	74
2025 Q4	$10.9M	Buy	+49,495	New	+$8M	0.24%	51

Duquesne Family Office's CDTX Position: Q1 2026 in Review

Duquesne Family Office sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 49,495 shares — an estimated $10.9M sold.

Duquesne Family Office first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $10.9M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Duquesne Family Office reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Duquesne Family Office sold 49,495 Cidara Therapeutics shares in Q1 2026, an estimated $10.9M.
Duquesne Family Office first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Duquesne Family Office's Cidara Therapeutics position peaked at $10.9M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Duquesne Family Office's 13F filing for Q1 2026, filed 15 May 2026.